Anti-POLR1A / DNA-directed RNA polymerase I subunit RPA1

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. POLR1A antibody detects DNA-directed RNA polymerase I subunit RPA1, the largest catalytic subunit of RNA polymerase I, which is responsible for ribosomal RNA (rRNA) synthesis in the nucleolus. Encoded by the POLR1A gene on chromosome 2p11.2, this essential enzyme subunit forms part of the multi-protein RNA polymerase I complex that catalyzes transcription of 45S pre-rRNA, a key step in ribosome biogenesis. POLR1A serves as the catalytic core that binds DNA and nucleoside triphosphates, driving polymerization during transcription initiation and elongation.Structurally, POLR1A contains a DNA-binding cleft, catalytic residues within the active center, and multiple contact surfaces for interacting with transcription factors and other RNA polymerase I subunits. It forms the backbone of the enzyme and interacts with RPA2 and RPA3 to establish the core complex. POLR1A also associates with transcription initiation factors such as SL1 and UBF, which guide polymerase recruitment to rDNA promoters and regulate transcriptional output in response to growth signals.The POLR1A antibody is widely used in transcription, cell growth, and cancer biology research to study ribosomal biogenesis and nucleolar function. Western blot analysis detects a 190 kilodalton band corresponding to POLR1A, while immunofluorescence reveals strong nucleolar staining consistent with its role in rRNA synthesis. This antibody supports studies of transcriptional regulation, nucleolar stress responses, and metabolic control of protein synthesis.POLR1A activity is tightly linked to cellular growth and proliferation. Under conditions of nutrient abundance, mTOR signaling promotes RNA polymerase I activation and rRNA transcription, conversely, DNA damage or stress inhibits POLR1A function to conserve resources. Mutations in POLR1A cause ribosomopathies such as acrofacial dysostosis, characterized by craniofacial malformations due to impaired ribosome production. Overactivation of RNA polymerase I, on the other hand, contributes to oncogenic transformation by driving excessive ribosome biogenesis and protein synthesis. The POLR1A antibody allows precise monitoring of polymerase expression and localization under these physiological and pathological conditions.NSJ Bioreagents provides a high-quality POLR1A antibody validated for its applications. Its sensitivity and specificity enable researchers to investigate transcriptional control mechanisms, nucleolar architecture, and the coupling of rRNA synthesis to cell cycle progression and oncogenesis.